Skip to main navigation
Leap therapeutics
Leap therapeutics
  • About
    • About
    • Contact Us
  • Pipeline
    • Pipeline
    • DKN-01 programs
      • Gastric Cancer
      • Colorectal Cancer
      • Endometrial Cancer
      • Prostate Cancer
      • Lung Cancer
    • Anti-CLDN18.2 programs
      • FL-301 (NBL-015)
      • FL-302 (NBL-016)
    • FL-501
  • Science
    • Science
    • DKK1
    • DKN-01
    • Claudin18.2
    • GDF15
  • Patients
    • Patients
    • Expanded Access
  • Careers
  • Investors
    • Investors
    • Stock Information
    • News Releases
    • Presentations & Events
    • Financial Information
    • Corporate Governance
    • Information Request

News
Releases

image description

News Releases

Mar 24, 2023
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 16, 2023
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01
Jan 17, 2023
Leap Therapeutics Acquires Flame Biosciences
Jan 11, 2023
Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference
  • image Print Page Print Page
  • image Email Alerts Email Alerts
  • image Contact Us Contact Us
image description
image description
Leap therapeutics
47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 USA
+1 617 714 0360

Business inquiries
bd@leaptx.com

Investor inquiries
ir@leaptx.com

  • ABOUT
  • CONTACT US
  • CAREERS
  • PIPELINE
  • DKN-01 PROGRAMS
  • ANTI-CLDN18.2 PROGRAMS
  • FL-501
  • PATIENTS
  • EXPANDED ACCESS
  • SCIENCE
  • DKK1
  • DKN-01
  • CLAUDIN18.2
  • GDF15
  • INVESTORS
  • STOCK INFORMATION
  • NEWS RELEASES
  • PRESENTATIONS & EVENTS
  • FINANCIAL INFORMATION
  • CORPORATE GOVERNANCE
  • INFORMATION REQUEST
  • © 2023 Leap Therapeutics, Inc.
  • All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • Cookie Policy